全文获取类型
收费全文 | 821篇 |
免费 | 51篇 |
国内免费 | 2篇 |
专业分类
耳鼻咽喉 | 12篇 |
儿科学 | 6篇 |
妇产科学 | 15篇 |
基础医学 | 69篇 |
口腔科学 | 16篇 |
临床医学 | 83篇 |
内科学 | 163篇 |
皮肤病学 | 4篇 |
神经病学 | 42篇 |
特种医学 | 56篇 |
外科学 | 93篇 |
综合类 | 5篇 |
预防医学 | 39篇 |
眼科学 | 3篇 |
药学 | 115篇 |
肿瘤学 | 153篇 |
出版年
2023年 | 4篇 |
2022年 | 6篇 |
2021年 | 11篇 |
2020年 | 8篇 |
2019年 | 17篇 |
2018年 | 15篇 |
2017年 | 5篇 |
2016年 | 11篇 |
2015年 | 14篇 |
2014年 | 24篇 |
2013年 | 36篇 |
2012年 | 50篇 |
2011年 | 45篇 |
2010年 | 35篇 |
2009年 | 44篇 |
2008年 | 37篇 |
2007年 | 40篇 |
2006年 | 38篇 |
2005年 | 35篇 |
2004年 | 42篇 |
2003年 | 35篇 |
2002年 | 33篇 |
2001年 | 27篇 |
2000年 | 25篇 |
1999年 | 27篇 |
1998年 | 13篇 |
1997年 | 21篇 |
1996年 | 12篇 |
1995年 | 11篇 |
1994年 | 11篇 |
1993年 | 14篇 |
1992年 | 19篇 |
1991年 | 15篇 |
1990年 | 7篇 |
1989年 | 9篇 |
1988年 | 13篇 |
1987年 | 7篇 |
1986年 | 7篇 |
1985年 | 3篇 |
1984年 | 5篇 |
1983年 | 3篇 |
1982年 | 2篇 |
1981年 | 2篇 |
1980年 | 3篇 |
1979年 | 5篇 |
1977年 | 3篇 |
1976年 | 6篇 |
1975年 | 7篇 |
1974年 | 2篇 |
1966年 | 2篇 |
排序方式: 共有874条查询结果,搜索用时 0 毫秒
871.
Gut peptides and the regulation of appetite 总被引:3,自引:0,他引:3
There is a growing worldwide epidemic of obesity. Obese people have a higher incidence of type 2 diabetes and cardiovascular disease, and hence present increasing social, financial and health burdens. Weight loss is always difficult to achieve through lifestyle changes alone, and currently licensed anti-obesity drug treatments, such as orlistat and sibutramine, if tolerated, only achieve modest weight loss. Therefore, there is a need to identify more potent pharmacological targets. In the last 10 years, discoveries of new hormones such as leptin and ghrelin, together with greater understanding of previously described hormones such as cholecystokinin (CCK), pancreatic polypeptide (PP), peptide YY (PYY) and glucagon-like peptide 1 (GLP-1), have led to a rapid increase in our knowledge of the regulation of energy balance. Among the most important factors, controlling appetite and satiety are peptide hormones released from the gut. In this paper, we provide a full up-to-date overview of the current state of knowledge of this field, together with the potential of these peptides as drugs, or as other therapeutic targets, in the treatment of obesity. Finally, we propose an integrated model to describe the complex interplay of these hormones in the broader physiology of energy balance. 相似文献
872.
Glenn Liu Jordan Berlin Kendra D Tutsch Lynn Van Ummersen Amy Dresen Rebecca Marnocha Rhoda Arzomanian Dona Alberti Chris Feierabend Kimberly Binger George Wilding 《Clinical cancer research》2002,8(3):706-711
Penclomedine is a synthetic alpha-picoline derivative that has shown antitumor activity both in preclinical development and in Phase I work using an i.v. preparation. The main toxicities seen in those studies were dose dependent and mainly neurocerebellar, with hematological toxicity being far less severe. This Phase I trial of p.o. penclomedine was conducted to potentially alter the toxicity profile and to avoid the neurological side effects seen with i.v. penclomedine. Eligibility criteria included microscopic confirmation of a solid malignancy or lymphoma with a lack of effective anticancer therapy. Twenty patients were enrolled. The median age was 60.5 years, and the median performance status was one. All but one patient had received prior systemic therapy. The starting dose of penclomedine was 200 mg/m(2) p.o. for 5 days, and was escalated according to a traditional Fibonacci sequence until the maximum tolerated dose (MTD) was observed. No treatment-related deaths were observed during the study. The MTD was determined to be 800 mg/m(2) p.o. for 5 days. Dose-limiting toxicities included mainly neurocerebellar symptoms such as ataxia and dysmetria, but neurocortical symptoms, such as confusion, were seen as well. Myelosuppression was less common and resulted in the discontinuation of therapy in only two patients. Pharmacokinetics show that the observed MTD is consistent with the i.v. preparations, and that the bioavailability of p.o. penclomedine is 49 +/- 18%. This regimen can be considered for additional studies in patients with intracranial neoplasms, because good central nervous system penetration is evident. Further development of penclomedine metabolites, such as 4-O-demethylpenclomedine, should be considered to minimize dose-limiting neurotoxicity. 相似文献
873.
874.